News Channels

11 Dec 2017 Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease
11 Dec 2017 Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
11 Dec 2017 Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
11 Dec 2017 ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402
11 Dec 2017 ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301
11 Dec 2017 Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting
11 Dec 2017 Argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
11 Dec 2017 Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
11 Dec 2017 Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
11 Dec 2017 Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
11 Dec 2017 Phase III IMmotion151 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death for the Initial Treatment of Certain People with Advanced Kidney Cancer
11 Dec 2017 Medigene collaborates with RXi Pharmaceuticals to further sharpen its therapeutic T cells
11 Dec 2017 ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting
10 Dec 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
10 Dec 2017 Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity
10 Dec 2017 Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
10 Dec 2017 Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
10 Dec 2017 Medivir announces Janssen decision to terminate its simeprevir license effective June 2018
10 Dec 2017 Phase II Data Showed Genentech’s Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma
10 Dec 2017 Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top